SCHEMBL13034755

SCHEMBL13034755

COC(=O)c1cc(Cc2ccc(NS(=O)(=O)c3ccc(C)cc3)c(C(=O)O)c2)ccc1NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ METAP2 P50579 7/20 0.61
▸ CYP2C9 P11712 3/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ FFAR4 Q5NUL3 1/20 0.55
▸ PTGDR2 Q9Y5Y4 1/20 0.53
▸ LMNA P02545 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HTT P42858 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ MCL1 Q07820 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13034754 0.95 FFAR4 (0.60) METAP2CYP2C9CYP1A2FFAR4PTGDR2
SCHEMBL14087834 0.93 METAP2 (0.70) METAP2CYP2C9CYP1A2PTGDR2LMNA
SCHEMBL13034736 0.92 METAP2 (0.53) METAP2CYP2C9CYP1A2FFAR4PTGDR2
SCHEMBL13034756 0.88 FFAR4 (0.52) METAP2CYP2C9CYP1A2FFAR4PTGDR2
SCHEMBL14397339 0.88 METAP2 (0.48) METAP2CYP2C9CYP1A2FFAR4PTGDR2
SCHEMBL13034766 0.87 METAP2 (0.62) METAP2CYP2C9CYP1A2PTGDR2LMNA
SCHEMBL14075202 0.87 METAP2 (0.62) METAP2CYP2C9CYP1A2PTGDR2LMNA
SCHEMBL3980105 0.87 METAP2 (0.81) METAP2CYP2C9CYP1A2PTGDR2LMNA
SCHEMBL13034757 0.85 METAP2 (0.60) METAP2CYP2C9CYP1A2PTGDR2LMNA
SCHEMBL13034765 0.83 LMNA (0.60) METAP2CYP2C9CYP1A2PTGDR2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280268-A1 HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-11-04 — — US disclosed
US-20100280268-A1 HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM TIBOTEC PHARMACEUTICALS LTD. (IE) 2010-11-04 — — US disclosed
WO-2007113337-A1 A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280268-A1 HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM C1QBP, CD4, CHRM4 METAP2 4039/4885CYP2C9 4489/4885CYP1A2 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback